Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Operating activities:
Net loss	$ (2,915,424)	$ (5,772,668)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization and depreciation	67,902	184,496
Amortization of discount on debt	7,281	4,328
Share-based compensation	453,935	414,112
Gain on settlement liability	(390,599)
Issuance of common stock for services	52,500	190,261
Change in fair value of warrant liability	(1,109,192)	907,368
Change in operating assets and liabilities:
Contracts and grants receivable	287,580	(1,069,976)
Prepaid expenses	18,653	14,770
Accounts payable and accrued expenses	206,881	1,343,876
Accrued compensation	(236,430)	(266,942)
Total adjustments	(641,489)	1,722,293
Net cash used in operating activities	(3,556,913)	(4,050,375)
Investing activities:
Purchases of office furniture and equipment	(7,161)	(22,098)
Net cash used in investing activities	(7,161)	(22,098)
Financing activities:
Proceeds from issuance of common stock pursuant to the equity line	1,639,110	1,615,025
Stock issuance costs associated with equity line purchase agreement	(41,381)	(171,091)
Repayment of notes payable	(300,000)
Proceeds from issuance of common stock to SciClone	3,000,000
Proceeds from exercise of warrants		1,136,771
Net cash provided by financing activities	4,297,729	2,580,705
Net increase (decrease) in cash and cash equivalents	733,655	(1,491,768)
Cash and cash equivalents at beginning of period	4,921,545	5,525,094
Cash and cash equivalents at end of period	5,655,200	4,033,326
Supplemental disclosure of non cash financing activities:
Reclassification of warrant liability to additional paid in capital upon partial exercise of warrants issued in unit offering		2,557,331
Notes payable issued in connection with Equity Purchase Agreement		$ 282,071